Skip to content

Optimized Oxygen Delivery During General Anesthesia in Newborn Infants

Oxygen Delivery During General Anesthesia in Newborn Infants: An Open Randomized Controlled Trial of Two Levels of Inspired Oxygen.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02698020
Acronym
ANOXneo
Enrollment
35
Registered
2016-03-03
Start date
2015-11-30
Completion date
2018-10-10
Last updated
2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxidative Stress, Oxygen Toxicity

Keywords

Newborn, Anesthesia, Oxygen, Hyperoxia

Brief summary

An open randomized control trial investigating the delivery of two levels of inspired oxygen to newborn infants during general anesthesia.

Detailed description

Eligible infants are infants of less than 44 weeks postconceptional age and without pulmonary disease or demand for supplemental oxygen or assisted ventilation. Control subjects receive current standard of care (anesthesia induction/pre-oxygenation with 80%, maintenance of anesthesia with 40%, and recovery with 80% inspired oxygen). Intervention subjects are maintained on room air throughout the procedure and supplemental oxygen added only if necessary according to the pre-specified oxygen saturation target. Subjects are monitored according to clinical protocols AND with cerebral oximetry (NIRS), transcutaneous measurement of partial pressure of oxygen (pO2), and blood-gas analyses. Blood and urine samples are collected for later analysis of markers for oxidative stress.

Interventions

PROCEDURERoom-air

Provision of room-air

Sponsors

Uppsala University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 4 Weeks
Healthy volunteers
No

Inclusion criteria

1. Newborn less than 44 weeks postconceptional age 2. No pulmonary disease, no oxygen requirement, or assisted ventilation 3. No genetic syndrome

Design outcomes

Primary

MeasureTime frameDescription
Transcutaneous and blood-gas pO230 minArea under curve (AUC) and absolute values of pO2

Secondary

MeasureTime frameDescription
Cerebral Oximetry30 minAUC of O2 saturation
Atelectasis30 minReduced lung compliance as a measure of atelectasis formation
Isoprostane4 hLevel of isoprostanes in blood and urine

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026